Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
Zoetis Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Invested capital2 | ||||||
Performance Ratio | ||||||
ROIC3 | ||||||
Benchmarks | ||||||
ROIC, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2023 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
- Net Operating Profit After Taxes (NOPAT)
- The net operating profit after taxes demonstrates a generally upward trend over the five-year period. Starting at $1,570 million in 2019, it increased steadily to $1,727 million in 2020 and then saw a more pronounced rise to $2,131 million in 2021. Although there was a slight decline to $1,958 million in 2022, the figure rebounded significantly in 2023 to $2,410 million, marking the highest value in the series.
- Invested Capital
- Invested capital showed an overall increase from 2019 through 2022, starting at $9,838 million and peaking at $12,542 million in 2022. However, in 2023, invested capital decreased to $11,550 million, indicating a reduction after several years of growth. This decline may suggest adjustments in asset allocation or capital efficiency efforts.
- Return on Invested Capital (ROIC)
- The return on invested capital fluctuated throughout the period but displays a notable improvement by the end of 2023. ROIC was 15.96% in 2019, experienced a slight decrease to 14.94% in 2020, followed by an increase to 18.36% in 2021. It dipped again to 15.61% in 2022 before rising significantly to 20.87% in 2023. This final increase suggests enhanced profitability relative to the capital invested, possibly driven by improved operating efficiency or higher margins.
- Overall Observations
- The company’s profitability metrics indicate a resilient and improving performance over the five years, with net operating profit after taxes and ROIC both reaching their highest levels in 2023. Despite fluctuations in invested capital, the ability to generate greater returns on capital in 2023 reflects positively on operational and financial management. The reduction in invested capital in the final year, paired with increased NOPAT and ROIC, may point to strategic capital optimization or divestitures enhancing overall capital efficiency.
Decomposition of ROIC
ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
---|---|---|---|---|---|---|---|
Dec 31, 2023 | = | × | × | ||||
Dec 31, 2022 | = | × | × | ||||
Dec 31, 2021 | = | × | × | ||||
Dec 31, 2020 | = | × | × | ||||
Dec 31, 2019 | = | × | × |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
- Operating Profit Margin (OPM)
- The operating profit margin has demonstrated a consistent upward trend over the five-year period. Starting at 31.81% in 2019, it gradually increased each year, reaching 36.25% in 2023. This indicates an improvement in operational efficiency and profitability, suggesting the company has been managing its operating costs effectively relative to its revenues.
- Turnover of Capital (TO)
- The turnover of capital ratio showed some variability throughout the period. It decreased from 0.64 in 2019 to 0.58 in 2020, reflecting a reduction in asset efficiency. However, it rebounded to 0.67 in 2021, then slightly declined to 0.64 in 2022 before rising to the highest value of 0.74 in 2023. The overall trend suggests a recovery and improvement in asset utilization toward the end of the period.
- 1 – Effective Cash Tax Rate (CTR)
- This metric remained relatively stable and high from 2019 through 2021, around the 78% range, indicating that a significant portion of earnings before tax was retained after cash taxes. In 2022, there was a notable drop to 69.3%, signifying a higher effective cash tax burden that year. In 2023, the rate rose again to 77.82%, closer to previous levels, indicating a return to the higher post-tax cash retention percentages.
- Return on Invested Capital (ROIC)
- The return on invested capital exhibited some fluctuations but overall showed an upward movement. Starting at 15.96% in 2019, it dipped to 14.94% in 2020, then increased significantly to 18.36% in 2021. There was a decrease to 15.61% in 2022, followed by a strong increase to 20.87% in 2023, the highest value in the series. This pattern suggests the company improved the efficiency and profitability of its capital investments, particularly in the most recent year.
Operating Profit Margin (OPM)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Revenue | ||||||
Profitability Ratio | ||||||
OPM3 | ||||||
Benchmarks | ||||||
OPM, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2023 Calculation
OPM = 100 × NOPBT ÷ Revenue
= 100 × ÷ =
4 Click competitor name to see calculations.
- Net Operating Profit Before Taxes (NOPBT)
- The net operating profit before taxes exhibited a consistent upward trend over the five-year period. Starting at $1,991 million in 2019, it increased annually to reach $3,097 million by 2023. This indicates a strong and steady improvement in profitability from operational activities.
- Revenue
- Revenue demonstrated a steady growth pattern throughout the timeframe. Beginning at $6,260 million in 2019, revenue rose each year, culminating in $8,544 million in 2023. This continuous increase suggests effective market expansion or enhanced sales performance.
- Operating Profit Margin (OPM)
- The operating profit margin showed a gradual but consistent increase over the analyzed periods. From 31.81% in 2019, it improved to 36.25% by 2023. This upward trend indicates rising operational efficiency, with the company generating a higher proportion of profit relative to its revenue.
- Overall Insights
- The data reveals a positive financial trajectory characterized by growing revenues, increasing net operating profits, and improving profit margins. Such trends reflect enhanced operational effectiveness, potentially driven by better cost management or favorable market conditions. The consistent expansion in both absolute profitability and margin percentage underscores a strengthening financial position over the five years.
Turnover of Capital (TO)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Revenue | ||||||
Invested capital1 | ||||||
Efficiency Ratio | ||||||
TO2 | ||||||
Benchmarks | ||||||
TO, Competitors3 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Invested capital. See details »
2 2023 Calculation
TO = Revenue ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
The financial data reveals several notable trends over the five-year period. Revenue exhibited a consistent upward trajectory, increasing from US$ 6,260 million in 2019 to US$ 8,544 million in 2023. This steady growth suggests an expanding business or successful market penetration. The most significant year-over-year increase occurred between 2020 and 2021, indicating possible operational improvements or favorable market conditions during that interval.
Invested capital also demonstrated growth, rising from US$ 9,838 million in 2019 to a peak of US$ 12,542 million in 2022 before declining to US$ 11,550 million in 2023. The increase in invested capital through 2022 may reflect ongoing investments in assets or business expansion efforts. The decline in 2023 could signal asset disposals, efficiency improvements, or changes in capital structure.
The turnover of capital (TO) ratio, which measures revenue generated per unit of invested capital, showed variability across the period. It started at 0.64 in 2019, dipped to 0.58 in 2020, then recovered to 0.67 in 2021. Subsequent years saw a slight decline to 0.64 in 2022 followed by an increase to 0.74 in 2023. This ratio indicates fluctuating efficiency in converting invested capital into revenue, with a notable improvement in 2023 suggesting enhanced asset utilization or operational efficiency.
- Revenue
- Consistent growth over five years with total increase of approximately 36.5% from 2019 to 2023.
- Invested Capital
- Growth until 2022 followed by a reduction in 2023, indicating adjustments in capital deployment.
- Turnover of Capital (TO)
- Initial decrease followed by recovery and overall improvement, reflecting variable but ultimately increased efficiency.
Effective Cash Tax Rate (CTR)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Tax Rate | ||||||
CTR3 | ||||||
Benchmarks | ||||||
CTR, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2023 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
- Cash Operating Taxes
- The cash operating taxes increased consistently from 2019 to 2022, rising from $422 million to $867 million, representing more than a doubling over the four-year period. However, in 2023, cash operating taxes decreased significantly to $687 million, marking a notable reduction from the previous year's peak.
- Net Operating Profit Before Taxes (NOPBT)
- NOPBT shows a clear upward trend throughout the entire period, advancing steadily each year from $1,991 million in 2019 to $3,097 million in 2023. This indicates a consistent growth in operational profitability before tax considerations, with the most substantial increase occurring between 2021 and 2023.
- Effective Cash Tax Rate (CTR)
- The effective cash tax rate remained relatively stable around 21% from 2019 through 2021. In 2022, there was a sharp increase to 30.7%, representing a significant rise in the percentage of operating profits paid as cash taxes. This rate then decreased in 2023 to 22.18%, nearly reverting to the levels observed before 2022.
- Overall Trends and Insights
- The company experienced steady growth in operating profitability before taxes over the five-year period. The cash taxes followed a similar upward trajectory through 2022, corresponding with rising profits and a higher effective tax rate that year. The spike in the effective cash tax rate in 2022 contributed to the peak in cash operating taxes despite relatively smaller increases in NOPBT. In 2023, although profits continued to grow, the effective tax rate declined significantly, which led to a reduction in cash operating taxes compared to the previous year. This pattern suggests a potential change in tax strategy, tax regulations, or one-time tax impacts affecting the 2022 fiscal year.